AtriCure Inc (ATRC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, AtriCure Inc (ATRC) has a cash flow conversion efficiency ratio of -0.008x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.00 Million) by net assets ($491.69 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See AtriCure Inc balance sheet quality to measure how much of total assets are equity-financed.
AtriCure Inc - Cash Flow Conversion Efficiency Trend (2004–2025)
This chart illustrates how AtriCure Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check earnings quality score of AtriCure Inc to evaluate the quality of earnings relative to operating cash generation.
AtriCure Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of AtriCure Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Chongqing Chuanyi Automation Co Ltd
SHG:603100
|
0.025x |
|
Tibet Tianlu Co Ltd
SHG:600326
|
0.030x |
|
Xinyu Iron & Steel Co Ltd
SHG:600782
|
0.050x |
|
Bangkok Life Assurance Public Company Limited
BK:BLA
|
0.044x |
|
Guangdong Ellington Electronics Technology Co Ltd
SHG:603328
|
0.053x |
|
Pearl Abyss Corp
KQ:263750
|
0.017x |
|
NÜRNBERGER Beteiligungs-AG
F:NBG6
|
-0.113x |
|
Nations Technologies Inc
SHE:300077
|
-0.129x |
Annual Cash Flow Conversion Efficiency for AtriCure Inc (2004–2025)
The table below shows the annual cash flow conversion efficiency of AtriCure Inc from 2004 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of AtriCure Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $491.94 Million | $57.33 Million | 0.117x | +340.22% |
| 2024-12-31 | $460.97 Million | $12.20 Million | 0.026x | +175.24% |
| 2023-12-31 | $466.17 Million | $4.48 Million | 0.010x | +119.84% |
| 2022-12-31 | $456.75 Million | $-22.14 Million | -0.048x | -70.17% |
| 2021-12-31 | $483.76 Million | $-13.78 Million | -0.028x | +40.88% |
| 2020-12-31 | $412.39 Million | $-19.87 Million | -0.048x | +24.63% |
| 2019-12-31 | $247.34 Million | $-15.81 Million | -0.064x | -282.19% |
| 2018-12-31 | $249.38 Million | $-4.17 Million | -0.017x | +69.86% |
| 2017-12-31 | $161.17 Million | $-8.94 Million | -0.055x | +38.17% |
| 2016-12-31 | $168.44 Million | $-15.12 Million | -0.090x | -113.68% |
| 2015-12-31 | $186.69 Million | $-7.84 Million | -0.042x | +74.22% |
| 2014-12-31 | $132.54 Million | $-21.60 Million | -0.163x | -126.59% |
| 2013-12-31 | $72.60 Million | $-5.22 Million | -0.072x | +53.56% |
| 2012-12-31 | $12.50 Million | $-1.94 Million | -0.155x | -21.75% |
| 2011-12-31 | $15.61 Million | $-1.99 Million | -0.127x | -6267.96% |
| 2010-12-31 | $16.74 Million | $-33.43K | -0.002x | -108.13% |
| 2009-12-31 | $17.09 Million | $419.95K | 0.025x | +112.53% |
| 2008-12-31 | $29.12 Million | $-5.71 Million | -0.196x | +12.45% |
| 2007-12-31 | $36.24 Million | $-8.12 Million | -0.224x | +44.85% |
| 2006-12-31 | $30.69 Million | $-12.47 Million | -0.406x | -130.28% |
| 2005-12-31 | $43.18 Million | $-7.62 Million | -0.176x | -226.84% |
| 2004-12-31 | $-27.33 Million | $-3.80 Million | 0.139x | -- |
About AtriCure Inc
AtriCure, Inc. engages in the development, manufacture, and sale of devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, the Asia-Pacific, and internationally. It offers Isolator Synergy Ablation System clamps, a single-use disposable radio frequency products; m… Read more